• Users Online: 1057
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 154-155

Multidisciplinary tumor board has another member – Molecular


Department of Integrated Oncopathology, Metropolis Healthcare Ltd., Mumbai, Maharashtra, India

Date of Submission31-Dec-2019
Date of Acceptance08-Jan-2020
Date of Web Publication24-Feb-2020

Correspondence Address:
Kirti Chadha
Department of Integrated Oncopathology, Metropolis Healthcare Ltd., Unit No. 409–416, 4th Floor, Commercial Building A, Kohinoor City, Near Kohinoor Mall, Kirol Road, Kurla-W, Mumbai - 400 070, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_131_19

Get Permissions


How to cite this article:
Chadha K, Vinarkar S, Chheda P. Multidisciplinary tumor board has another member – Molecular. Cancer Res Stat Treat 2020;3:154-5

How to cite this URL:
Chadha K, Vinarkar S, Chheda P. Multidisciplinary tumor board has another member – Molecular. Cancer Res Stat Treat [serial online] 2020 [cited 2020 Mar 30];3:154-5. Available from: http://www.crstonline.com/text.asp?2020/3/1/154/279090



Cancer patients harbor genomic alterations that are either recognized as biomarkers for optimal treatment selection or carry genomic aberrations with enough clinical evidence supporting their use as predictive biomarkers for drug response outside the registered indication.[1] With the generation of vast amount of genomic data by the use of next-generation sequencing (NGS) technology, correct interpretation of molecular tumor profiles is extremely important for optimal patient care. To address this, leading cancer-care providers have institutionalized 'Molecular Tumor Boards' (MTBs) to bring together cancer experts from across the network to discuss treatment plans based on a patient's molecular profile.

Kapoor et al. described a series of molecular aberrations detected in a 62-year-old female diagnosed with non-small cell lung cancer.[2] Besides a classical epidermal growth factor receptor (EGFR)-activating mutation detected on real-time polymerase chain reaction (PCR) and increased PD-L1 expression by IHC, amplifications of MYCN, FGFR3, EGFR, and MYC, along with variants of unknown significance in ALK, FGFR4, MET, and BRCA1, were detected by NGS, indicating high intratumor heterogeneity. Despite the presence of multiple mutations, the patient was initiated on and continues to be on afatinib (EGFR-directed therapy) based on real-time PCR results of EGFR as per the decision made in the MTB. However, authors have clearly outlined several treatment options such as anti-PD-L1, MET inhibitor, and combination of EGFR-TKIs and checkpoint inhibitors based on Phase I and Phase II studies in the article.

In sync with the complexity and heterogeneity of the lung cancer molecular signature highlighted by the authors, our institution is also validating a similar approach. This approach addresses major concerns related to the depletion of tumor tissue on sequential testing and also improves turnaround time for tumor profiling while reducing cost. Hence, if we replace multiple technology-dependent sequential testing with NGS-based concurrent detection of actionable variants and fusions, it will have multiple advantages.

Although the initial choice of treatment is based on biomarkers that predict response or resistance to the US FDA-approved therapies, off-label drugs can be considered based on prognostic significance of certain other NGS variants.[3] It is vital to educate physicians and clinicians on molecular profiling assays and their interpretation and also the strengths and pitfalls of technologies which would further help in treatment decisions.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
van de Haar J, Hoes L, Voest E. Advancing molecular tumour boards: Highly needed to maximise the impact of precision medicine. ESMO Open 2019;4:e000516.  Back to cited text no. 1
    
2.
Kapoor A, Noronha V, Chougule A, Patil VM, Menon N, Joshi A, et al. Molecular tumor board: Case 1-Interplay of EGFR, MET and PD-L1 in non-small cell lung carcinoma. Cancer Res Stat Treat 2019;2:228-31.  Back to cited text no. 2
  [Full text]  
3.
Perera-Bel J, Hutter B, Heining C, Bleckmann A, Fröhlich M, Fröhling S, et al. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. Genome Med 2018;10:18.  Back to cited text no. 3
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed59    
    Printed0    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal